Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

Acta Neuropathologica

Volumn 133, Issue 1, 2017, Pages 149-151

  Smith, Ruben ^a,b   Schöll, Michael ^b,c   Honer, Michael ^d   Nilsson, Christer F ^a,b   Englund, Elisabet ^e   Hansson, Oskar ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLORTAUCIPIR F 18; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; MAPT PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

AGED; ASTROCYTE; BASAL GANGLION; BRAIN ATROPHY; BRAIN CORTEX; BRAIN STEM; CASE REPORT; CELL BODY; DRUG UPTAKE; FRONTAL CORTEX; GLOBUS PALLIDUS; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MALE; MESENCEPHALON; MOLECULAR PATHOLOGY; NEURITE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; SILVER STAINING; STEREOLOGY; SUBSTANTIA NIGRA; TEMPORAL CORTEX; VOXEL BASED MORPHOMETRY; WHITE MATTER; BRAIN; DIAGNOSTIC IMAGING; FATALITY; METABOLISM; PATHOLOGY;

AGED; BRAIN; CARBOLINES; FATAL OUTCOME; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 85000624340     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1650-1     Document Type: Letter

References (8)

1. Hansen AK, Knudsen K, Lillethorup TP et al (2016) In vivo imaging of neuromelanin in Parkinson’s disease using 18F-AV-1451 PET. Brain. doi:10.1093/brain/aww098
2. Josephs KA, Whitwell JL, Tacik P et al (2016) [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 132:931–933. doi:10.1007/s00401-016-1618-1
3. Lowe VJ, Curran G, Fang P et al (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4:58. doi:10.1186/s40478-016-0315-6
4. Marquie M, Normandin MD, Vanderburg CR et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800. doi:10.1002/ana.24517
5. McMillan CT, Irwin DJ, Nasrallah I et al (2016) Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 132:935–937. doi:10.1007/s00401-016-1640-3
6. Sander K, Lashley T, Gami P et al (2016) Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement. doi:10.1016/j.jalz.2016.01.003
7. Smith R, Puschmann A, Scholl M et al (2016) 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139:2372–2379. doi:10.1093/brain/aww163
8. Smith R, Schain M, Nilsson C et al (2016) Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord. doi:10.1002/mds.26813